Over Two Years of Sustained Remission With Olaparib Monotherapy in Stage IV Non-Small Cell Lung Cancer With ATM...

Area of Science:

• Oncology
• Genetics
• Pharmacology

Background:

• Ataxia telangiectasia mutated (ATM) mutations are the most frequent homologous recombination deficiency (HRD) in non-small cell lung cancer (NSCLC).
• The therapeutic implications of ATM mutations in NSCLC remain largely unestablished.
• Homologous recombination deficiency (HRD) is a critical factor in DNA repair and cancer progression.

Observation:

• A case study of a 91-year-old male with metastatic NSCLC who had progressed through multiple treatment regimens.
• Next-generation sequencing identified ATM mutations in the patient's tumor.
• The patient was subsequently treated with olaparib, a PARP inhibitor.

Findings:

• Olaparib treatment resulted in a successful two-year remission for the patient.
• The patient's response indicates a positive correlation between ATM mutations and olaparib efficacy.
• Molecular testing identified actionable mutations, guiding personalized treatment.

Implications:

• This case highlights the potential of olaparib as a targeted therapy for NSCLC patients with HRD, specifically ATM mutations.
• The findings emphasize the importance of comprehensive molecular profiling for identifying patients who may benefit from targeted agents.
• Personalized medicine approaches, guided by genetic testing, are crucial for improving outcomes in NSCLC.